Effectiveness of methylphenidate in children and adolescents with KBG syndrome: An N-of-1 series

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506202-40-01

Acronym

113883

Enrollment

Registered

2024-06-27

Start date

2024-10-01

Completion date

Unknown

Last updated

2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

KBG syndrome

Brief summary

Strenghts and Difficulties Questionnaire, ADHD subscale

Detailed description

SDQ, emotional problems subscale, Dutch shortened version of the Emotion Dysregulation Inventory (EDI) reactivity index, Goal Attainment Scoring (GAS), Personal Questionnaire (PQ), Adverse Effects checklist for methylphenidate, McMaster Family assessment device (FAD), subscale General Functioning, Previous IQ test results, ADOS-2

Interventions

DRUGMethylphenidate Hydrochloride 5 mg Tablets

DRUGMicrocrystalline cellulose

DRUGMethylphenidate Hydrochloride 10 mg Tablets

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Strenghts and Difficulties Questionnaire, ADHD subscale	—

Secondary

Measure	Time frame
SDQ, emotional problems subscale, Dutch shortened version of the Emotion Dysregulation Inventory (EDI) reactivity index, Goal Attainment Scoring (GAS), Personal Questionnaire (PQ), Adverse Effects checklist for methylphenidate, McMaster Family assessment device (FAD), subscale General Functioning, Previous IQ test results, ADOS-2	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026